Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement

Fausto Biancari, Sebastian Dahlbacka, Tatu Juvonen, Marko P.O. Virtanen, Pasi Maaranen, Jussi Jaakkola, Teemu Laakso, Matti Niemelä, Tuomas Tauriainen, Antti Vento, Annastiina Husso, Mikko Savontaus, Mika Laine, Timo Mäkikallio, Peter Raivio, Markku Eskola, Stefano Rosato, Vesa Anttila, Juhani Airaksinen, Antti Valtola

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review


Aim The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer. Methods This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017. Results In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p 
TidskriftInternational Journal of Cardiology
StatusPublicerad - 18 mar 2020
MoE-publikationstypA1 Tidskriftsartikel-refererad


  • 3122 Cancersjukdomar

Citera det här